Elisa Bennicelli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Elisa Bennicelli has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
- Eugenia Cella
Department of Internal Medicine and Medical Specialties (DIMI), School of Medicine, University of Genova , Genova
3 shared publications - Pietro Fiaschi
Division of Neurosurgery, Ospedale Policlinico San Martino, IRCCS for Oncology and Neurosciences, Largo Rosanna Benzi 10, 16132 Genoa, Italy
3 shared publications - Camilla Satragno
Inserm U1030 Radiothérapie Moléculaire et Innovation Thérapeutique, Gustave Roussy, Université Paris-Saclay, Villejuif, France
2 shared publications - Carlo Genova
Department of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy; Academic Medical Oncology Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
2 shared publications - D. Esposito
Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy
2 shared publications F Giannelli
Division of Radiotherapy; IRCCS Ospedale Policlinico San Martino , Genoa , Italy
2 shared publications
Latest Publications
- Open Access
- 13 July 2026
- Published by Elsevier in SSRN Electronic Journal
Financial toxicity, Socioeconomic Status, and clinical outcome in Glioblastoma: the ISES-2 Prospective Multicenter Italian Study
BackgroundGlioblastoma (GBM) is an aggressive brain tumor with poor survival despite multimodal treatment. The impact of socioeconomic status (SES) and financial toxicity (FT) in GBM remains poorly defined.Patients and methodsThis prospective observational study involved 19 Italian centers and evaluated the association between SES, financial toxicity (FT), biological and clinical variables, and outcomes in newly diagnosed GBM patients within the Italian universal healthcare system. SES and FT data were collected at the start of radiochemotherapy and after 6 months using structured questionnaires, including the Patient Reported Outcome for Fighting FInancial Toxicity (PROFFIT) questionnaire for FT assessment.ResultsBetween March 2021 and September 2024, 405 patients were enrolled; 385 had evaluable baseline questionnaires and 374 histologically confirmed GBM were included in survival analyses. Mean (SD) PROFFIT score was 32.8 (24.2). Higher FT was associated with younger age (p <0.001), foreign birth (p <0.001), dependent family members (p=0.046), unemployment/work disability (p <0.001), work discontinuation (p=0.005), and lower income (p <0.001). FT was also strongly associated with worsening physical appearance and sexual activity (both p<0.001). Caregiver burden was substantial, with 52.2% reducing working hours and 11.6% leaving work due to the patient’s illness. PROFFIT score was not associated with PFS or OS.Conclusions The study showed that FT is a significant issue in GBM, particularly among vulnerable patients, even within a universal healthcare system. The high caregiver burden supports routine FT assessment and health policies aimed at reducing the economic and psychosocial impact of the disease.
- 13 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessFinancial toxicity, Socioeconomic Status, and clinical outcome in Glioblastoma: the ISES-2 Prospective Multicenter Italian Study
BackgroundGlioblastoma (GBM) is an aggressive brain tumor with poor survival despite multimodal treatment. The impact of socioeconomic status (SES) and financial toxicity (FT) in GBM remains poorly defined.Patients and methodsThis prospective observational study involved 19 Italian centers and evaluated the association between SES, financial toxicity (FT), biological and clinical variables, and outcomes in newly diagnosed GBM patients within the Italian universal healthcare system. SES and FT data were collected at the start of radiochemotherapy and after 6 months using structured questionnaires, including the Patient Reported Outcome for Fighting FInancial Toxicity (PROFFIT) questionnaire for FT assessment.ResultsBetween March 2021 and September 2024, 405 patients were enrolled; 385 had evaluable baseline questionnaires and 374 histologically confirmed GBM were included in survival analyses. Mean (SD) PROFFIT score was 32.8 (24.2). Higher FT was associated with younger age (p <0.001), foreign birth (p <0.001), dependent family members (p=0.046), unemployment/work disability (p <0.001), work discontinuation (p=0.005), and lower income (p <0.001). FT was also strongly associated with worsening physical appearance and sexual activity (both p<0.001). Caregiver burden was substantial, with 52.2% reducing working hours and 11.6% leaving work due to the patient’s illness. PROFFIT score was not associated with PFS or OS.Conclusions The study showed that FT is a significant issue in GBM, particularly among vulnerable patients, even within a universal healthcare system. The high caregiver burden supports routine FT assessment and health policies aimed at reducing the economic and psychosocial impact of the disease.
- Open Access
- 1 September 2023
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 25 (Supplement) , ii77-ii78
P11.23.A GLIOBLASTOMA MOLECULAR CORRELATES OF SEIZURE OCCURRENCE/RECURRENCE AFTER SURGERY: THE ROLE OF P53 MUTATION
The integration of molecular data and histology changed the diagnostic approach and prognostic characterization for patients with brain tumors. The aim of this study is identify molecular risk factors associated with seizure occurrence and/or recurrence after surgery in patients with brain glioblastoma. Patients with brain glioblastoma were consecutively enrolled and underwent brain surgery, followed by histopathological and molecular evaluation. Immuno-histochemical, molecular (synaptophysin, GFAP, ATRX, p53, ki67 index and MGMT gene promoter methylation) and clinical (age, sex and seizure occurrence/recurrence before and/or after surgery) data were collected. Histopathological and molecular features were compared between patients with and without seizure occurrence/recurrence after surgery. A step-backward logistic regression was performed to investigate the association between molecular features and seizure occurrence/recurrence. 100 patients (age 59.51±1.23, 65 males) were enrolled. Forty-nine patients had seizures before surgery. After surgery, 40 patients (age 59.43±1.64, 27 males) had seizure occurrence/recurrence, while 60 (age 59.57±1.75, 38 males) had not. Patients with epilepsy (i.e., seizures before and/or after surgery) had lower synaptophysin (33.33%, p=0.008) and higher p53 (85%, p=0.038) mutation rate compared with patients without epilepsy. In the whole sample, seizure occurrence/recurrence after surgery was significantly associated with p53 mutation (OR: 3.9, CI 1.12-13.50, p=0.032) and seizure occurrence before surgery (OR: 5.3, CI 2.15-13.08, p<0.001). In patients without seizures before surgery, p53 mutation perfectly predicted seizure occurrence, therefore the OR was not computable. In fact, all patients without p53 mutation didn’t have seizure after surgery, while all patients that had seizure after surgery, also had p53 mutation (p=0.028). However, to note 71% patients with p53 mutation didn’t have seizure after surgery. The p53 mutation is related with a high risk of seizure occurrence/recurrence after surgery in brain glioblastoma, even in patients that didn’t have seizures before surgery. Conversely, the absence of p53 mutation appears to protect against the occurrence of seizures. If confirmed, this result may help in the management of anti-seizure treatment after surgery in brain glioblastoma patients.
- 1 September 2023
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 25 (Supplement) , ii77-ii78
Open AccessP11.23.A GLIOBLASTOMA MOLECULAR CORRELATES OF SEIZURE OCCURRENCE/RECURRENCE AFTER SURGERY: THE ROLE OF P53 MUTATION
The integration of molecular data and histology changed the diagnostic approach and prognostic characterization for patients with brain tumors. The aim of this study is identify molecular risk factors associated with seizure occurrence and/or recurrence after surgery in patients with brain glioblastoma. Patients with brain glioblastoma were consecutively enrolled and underwent brain surgery, followed by histopathological and molecular evaluation. Immuno-histochemical, molecular (synaptophysin, GFAP, ATRX, p53, ki67 index and MGMT gene promoter methylation) and clinical (age, sex and seizure occurrence/recurrence before and/or after surgery) data were collected. Histopathological and molecular features were compared between patients with and without seizure occurrence/recurrence after surgery. A step-backward logistic regression was performed to investigate the association between molecular features and seizure occurrence/recurrence. 100 patients (age 59.51±1.23, 65 males) were enrolled. Forty-nine patients had seizures before surgery. After surgery, 40 patients (age 59.43±1.64, 27 males) had seizure occurrence/recurrence, while 60 (age 59.57±1.75, 38 males) had not. Patients with epilepsy (i.e., seizures before and/or after surgery) had lower synaptophysin (33.33%, p=0.008) and higher p53 (85%, p=0.038) mutation rate compared with patients without epilepsy. In the whole sample, seizure occurrence/recurrence after surgery was significantly associated with p53 mutation (OR: 3.9, CI 1.12-13.50, p=0.032) and seizure occurrence before surgery (OR: 5.3, CI 2.15-13.08, p<0.001). In patients without seizures before surgery, p53 mutation perfectly predicted seizure occurrence, therefore the OR was not computable. In fact, all patients without p53 mutation didn’t have seizure after surgery, while all patients that had seizure after surgery, also had p53 mutation (p=0.028). However, to note 71% patients with p53 mutation didn’t have seizure after surgery. The p53 mutation is related with a high risk of seizure occurrence/recurrence after surgery in brain glioblastoma, even in patients that didn’t have seizures before surgery. Conversely, the absence of p53 mutation appears to protect against the occurrence of seizures. If confirmed, this result may help in the management of anti-seizure treatment after surgery in brain glioblastoma patients.
- Open Access
- 1 September 2023
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 25 (Supplement) , ii91-ii92
P11.71.B THE MULTIDISCIPLINARY METHOD TO DISTINGUISH TRUE TUMOUR PROGRESSION FROM PSEUDOPROGRESSION IN HIGH GRADE GLIOMA VIA THE SYSTEMIC INFLAMMATORY MARKERS
To identify the role of serum inflammatory markers and T1-gadolinium volume (T1GV) post-radiotherapy (RT), in the multidisciplinary approach to differentiate true tumor progression (TTP) from pseudo-progression (PsP) in high-grade glioma (HGG) patients. A retrospective cohort of HGG (WHO 2021) was consecutively enrolled from 2015 to 2021. Clinical, instrumental, and therapeutic data were collected at diagnosis, treatment and within 6 months after the end of RT.The response to treatment was assessed according to the modified RANO criteria; volumetry of suspected progression was performed on T1G and FLAIR. Blood tests also included the analysis of the neutrophil/lymphocyte ratio (NLR), systemic immune-inflammatory index (SII) and systemic inflammatory response index (SIRI). Patients with suspected progression underwent a new MRI within 3 months of the first one.Any association between the clinicopathological factors and the presence of progression were analysed by Chi-square and Fisher’s exact test. Differences between group in continuous variables were assessed by independent sample-T test or Mann-Whitney U test, as appropriate. Prognostic factors for progression were investigated with a regression logistic model where predictors were log-transformed owing to their skewed distribution. Due to an existing multicollinearity in the common multivariate regression model between the variables “NLR” and “SII index”, two further separate binary regression models were set up, whereby in the “Multivariate Model NLR” the SII index was not considered and in the “Multivariate Model SII index” the NLR was not included. A Cox regression analysis was conducted to assess the impact of PsP- and TTP-related factors on overall survival (OS). 39 patients (41.0% females) were included, 16 showed PsP and 23 TTP.NLR, SII and T1 gadolinium volume were higher in the TTP group than in PsP (respectively 4.7 vs 2.8, p= 0.002; 890.5 vs 546.5, p = 0.009; and 11.7 cm3 vs 2.2 cm3, pOR 2.7, CI 95% 1.3 to 5.5, p=0.006)] and SII [OR 4.2, 95%CI: 1.1 to 15.3, p=0.030].The OS was significantly worsened in patients with TTP compared to patients with PsP [HR 3.97, 95%CI: 1.59 to 9.93, p = 0.003]. At multivariate analysis other factors did not impact the overall survival. Higher NLR, SII and T1GV showed good sensitivity and specificity to differentiate between PsP and TTP.Further studies with larger cohorts are needed to evaluate the inclusion of inflammatory indices and volumetry in the differentiation diagram of PsP from TTP.
- 1 September 2023
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 25 (Supplement) , ii91-ii92
Open AccessP11.71.B THE MULTIDISCIPLINARY METHOD TO DISTINGUISH TRUE TUMOUR PROGRESSION FROM PSEUDOPROGRESSION IN HIGH GRADE GLIOMA VIA THE SYSTEMIC INFLAMMATORY MARKERS
To identify the role of serum inflammatory markers and T1-gadolinium volume (T1GV) post-radiotherapy (RT), in the multidisciplinary approach to differentiate true tumor progression (TTP) from pseudo-progression (PsP) in high-grade glioma (HGG) patients. A retrospective cohort of HGG (WHO 2021) was consecutively enrolled from 2015 to 2021. Clinical, instrumental, and therapeutic data were collected at diagnosis, treatment and within 6 months after the end of RT.The response to treatment was assessed according to the modified RANO criteria; volumetry of suspected progression was performed on T1G and FLAIR. Blood tests also included the analysis of the neutrophil/lymphocyte ratio (NLR), systemic immune-inflammatory index (SII) and systemic inflammatory response index (SIRI). Patients with suspected progression underwent a new MRI within 3 months of the first one.Any association between the clinicopathological factors and the presence of progression were analysed by Chi-square and Fisher’s exact test. Differences between group in continuous variables were assessed by independent sample-T test or Mann-Whitney U test, as appropriate. Prognostic factors for progression were investigated with a regression logistic model where predictors were log-transformed owing to their skewed distribution. Due to an existing multicollinearity in the common multivariate regression model between the variables “NLR” and “SII index”, two further separate binary regression models were set up, whereby in the “Multivariate Model NLR” the SII index was not considered and in the “Multivariate Model SII index” the NLR was not included. A Cox regression analysis was conducted to assess the impact of PsP- and TTP-related factors on overall survival (OS). 39 patients (41.0% females) were included, 16 showed PsP and 23 TTP.NLR, SII and T1 gadolinium volume were higher in the TTP group than in PsP (respectively 4.7 vs 2.8, p= 0.002; 890.5 vs 546.5, p = 0.009; and 11.7 cm3 vs 2.2 cm3, pOR 2.7, CI 95% 1.3 to 5.5, p=0.006)] and SII [OR 4.2, 95%CI: 1.1 to 15.3, p=0.030].The OS was significantly worsened in patients with TTP compared to patients with PsP [HR 3.97, 95%CI: 1.59 to 9.93, p = 0.003]. At multivariate analysis other factors did not impact the overall survival. Higher NLR, SII and T1GV showed good sensitivity and specificity to differentiate between PsP and TTP.Further studies with larger cohorts are needed to evaluate the inclusion of inflammatory indices and volumetry in the differentiation diagram of PsP from TTP.
- 24 July 2023
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 182, S906
PO-1133 Potential role of pre-radiotherapy MRI for target delineation in high-grade gliomas
- 24 July 2023
- Published by Elsevier in Radiotherapy and Oncology
- Vol. 182, S906
PO-1133 Potential role of pre-radiotherapy MRI for target delineation in high-grade gliomas
- 1 September 2020
- Published by Elsevier in Annals of Oncology
- Vol. 31, S825-S826
1277P An exosomal miRNA signature as predictor of benefit from immune checkpoint inhibitors in non-small cell lung cancer
- 1 September 2020
- Published by Elsevier in Annals of Oncology
- Vol. 31, S825-S826
1277P An exosomal miRNA signature as predictor of benefit from immune checkpoint inhibitors in non-small cell lung cancer
- 20 May 2013
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 31 (15_suppl) , e14657
Double KRAS and BRAF mutations in colorectal cancer in a single oncologic department series.
E14657 Background: KRAS and BRAF mutations have prognostic and predictive value in colorectal cancer and are predominantly mutually exclusive. Only a few cases of double mutations (DM) have been reported so far but the actual incidence and presumed role in worsening prognosis is still unknown. Here we report on a series of KRAS and BRAF mutations, focusing on three cases of KRAS and BRAF DM. Methods: since May 2010, 316 consecutive colorectal cancer samples were collected by our Oncology Department; ten patients (3%) had high risk localized disease and 306 (97%) metastatic disease. Genome DNA from formalin-fixed paraffin embedded samples with tumor cells > 50% was analyzed by reverse dot blot with KRAS-BRAF StripAssay kit (Nuclear Laser Medicine). Results: KRAS point mutations were found in 141 patients (44.6%): 32% G12V, 30.5% G12D, 14.9% G13D, 6.4% G12S, 5.7% G12C, 4.9% G12A, 4.9% G12R, 0.7% G13C; V600E BRAF point mutation was found in 21 patients (6.6%). Three patients (1%) displayed DM: 2 KRAS G13D + BRAF V600E (A and B) and 1 KRAS G12V + BRAF V600E (C). Patients A and C, both aged 59, presented with metastatic disease. Patient A had a rectal primary, a single lung lesion and mediastinal nodes. He failed first line FOLFOX4 plus bevacizumab and underwent salvage surgery both on primary and metastatic disease. He relapsed in 3 months with liver and brain metastasis and died after one year from diagnosis. Patient B had huge liver lesions at presentation. She progressed after 3 courses of FOLFIRI and died after 6 months from diagnosis. Patient C was operated on for a right colon cancer, G3, pT2N2, stage IIIB with lymph vascular invasion and had adjuvant FOLFOX 4. The 6-month assessment did not show relapse. Conclusions: in our series KRAS mutation incidence was in line with literature, but G12V was far more frequent. KRAS-BRAF DM accounted for 1% of all cases and the 2 patients with metastatic disease had an aggressive course with a much lower than expected survival. To our knowledge no series of DM have been described, hindering the understanding of their biological meaning. According to our experience, metastatic double mutated patients do not respond to standard therapy and should be treated with new drugs combinations in clinical trials.
- 20 May 2013
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 31 (15_suppl) , e14657
Double KRAS and BRAF mutations in colorectal cancer in a single oncologic department series.
E14657 Background: KRAS and BRAF mutations have prognostic and predictive value in colorectal cancer and are predominantly mutually exclusive. Only a few cases of double mutations (DM) have been reported so far but the actual incidence and presumed role in worsening prognosis is still unknown. Here we report on a series of KRAS and BRAF mutations, focusing on three cases of KRAS and BRAF DM. Methods: since May 2010, 316 consecutive colorectal cancer samples were collected by our Oncology Department; ten patients (3%) had high risk localized disease and 306 (97%) metastatic disease. Genome DNA from formalin-fixed paraffin embedded samples with tumor cells > 50% was analyzed by reverse dot blot with KRAS-BRAF StripAssay kit (Nuclear Laser Medicine). Results: KRAS point mutations were found in 141 patients (44.6%): 32% G12V, 30.5% G12D, 14.9% G13D, 6.4% G12S, 5.7% G12C, 4.9% G12A, 4.9% G12R, 0.7% G13C; V600E BRAF point mutation was found in 21 patients (6.6%). Three patients (1%) displayed DM: 2 KRAS G13D + BRAF V600E (A and B) and 1 KRAS G12V + BRAF V600E (C). Patients A and C, both aged 59, presented with metastatic disease. Patient A had a rectal primary, a single lung lesion and mediastinal nodes. He failed first line FOLFOX4 plus bevacizumab and underwent salvage surgery both on primary and metastatic disease. He relapsed in 3 months with liver and brain metastasis and died after one year from diagnosis. Patient B had huge liver lesions at presentation. She progressed after 3 courses of FOLFIRI and died after 6 months from diagnosis. Patient C was operated on for a right colon cancer, G3, pT2N2, stage IIIB with lymph vascular invasion and had adjuvant FOLFOX 4. The 6-month assessment did not show relapse. Conclusions: in our series KRAS mutation incidence was in line with literature, but G12V was far more frequent. KRAS-BRAF DM accounted for 1% of all cases and the 2 patients with metastatic disease had an aggressive course with a much lower than expected survival. To our knowledge no series of DM have been described, hindering the understanding of their biological meaning. According to our experience, metastatic double mutated patients do not respond to standard therapy and should be treated with new drugs combinations in clinical trials.